These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 9082150)

  • 1. [Glycoprotein IIb/IIIa receptor inhibitors].
    Bornkessel B
    Med Monatsschr Pharm; 1996 Dec; 19(12):356-8. PubMed ID: 9082150
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists.
    Kleiman NS
    Coron Artery Dis; 1998; 9(9):603-16. PubMed ID: 9861523
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor.
    Weisman HF; Schaible TF; Jordan RE; Cabot CF; Anderson KM
    Biochem Soc Trans; 1995 Nov; 23(4):1051-7. PubMed ID: 8654680
    [No Abstract]   [Full Text] [Related]  

  • 4. Local delivery of glycoprotein IIb/IIIa receptor inhibitors using drug eluting stents.
    Gershlick AH
    Semin Interv Cardiol; 1998; 3(3-4):185-90. PubMed ID: 10406691
    [No Abstract]   [Full Text] [Related]  

  • 5. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycoprotein IIb/IIIa inhibition enhances platelet nitric oxide release.
    Chakrabarti S; Clutton P; Varghese S; Cox D; Mascelli MA; Freedman JE
    Thromb Res; 2004; 113(3-4):225-33. PubMed ID: 15140587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycoprotein IIb/IIIa inhibitors.
    Lincoff AM
    J Invasive Cardiol; 2004 Jul; 16(7 Suppl):11S-16S. PubMed ID: 23573566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonists c7E3 Fab on the activated clotting time.
    Levy JH; Kelley A
    Circulation; 1997 Nov; 96(10):3793-4. PubMed ID: 9396497
    [No Abstract]   [Full Text] [Related]  

  • 10. Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes.
    Melandri G
    Lancet; 2001 Dec; 358(9297):1997. PubMed ID: 11747953
    [No Abstract]   [Full Text] [Related]  

  • 11. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies].
    Internist (Berl); 1998 Dec; 39(12 Suppl Plattchena):1-4. PubMed ID: 10101692
    [No Abstract]   [Full Text] [Related]  

  • 13. Unsticking platelets: the role of glycoprotein IIb/IIIa receptor blockade.
    Armstrong PW
    CMAJ; 1999 Nov; 161(11):1423-4. PubMed ID: 10906900
    [No Abstract]   [Full Text] [Related]  

  • 14. [GPIIb/IIIa inhibitor].
    Ikeda Y
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1174-81. PubMed ID: 10771692
    [No Abstract]   [Full Text] [Related]  

  • 15. Duration of action of GpIIb-IIIa antagonists.
    Johnson K
    Crit Care Nurse; 2000 Oct; 20(5):16. PubMed ID: 11878484
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of thrombin inhibitors and a glycoprotein IIb/IIIa receptor antagonist in an ex vivo human experimental thrombosis model.
    Zokai K; Piazolo L; Harenberg J
    Semin Thromb Hemost; 2001 Oct; 27(5):531-6. PubMed ID: 11668424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
    Klinkhardt U; Kirchmaier CM; Westrup D; Graff J; Mahnel R; Breddin HK; Harder S
    Clin Pharmacol Ther; 2000 Mar; 67(3):305-13. PubMed ID: 10741635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newer therapeutic concept in antiplatelet aggregation inhibition--GPIIb-IIIa receptor antagonists.
    Malhotra S; Mishra NK; Sinha RS; Gupta B
    J Assoc Physicians India; 2000 Mar; 48(3):329-34. PubMed ID: 11229122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
    Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.